Jason M. Redman, M.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 13N240
- Bethesda, MD 20892
- 301-496-4000
- jason.redman@nih.gov
RESEARCH SUMMARY
Dr. Redman is a physician treating cancer patients with combinations of immunotherapy, chemotherapy and other therapies. He works on clinical trials for patients with prostate cancer, colon cancer, head and neck cancer, and other solid tumors.
The immune system is a complex network traditionally known for fighting infections. However, it can also fight cancer. Cancer immunotherapy refers to drug treatments designed to help the immune system recognize and fight cancer. In some cases, these treatments can lead to significant and long-lasting decreases in cancer burden. Dr. Redman is a member of the Center for Immuno-Oncology (CIO). He works closely with scientists who study the effects of immunotherapy on cancer in the laboratory. This research guides selection of drug combinations for use in clinical trials.
Areas of Expertise
1) combination immunotherapy for cancer 2) therapeutic cancer vaccines 3) colon cancer 4) prostate cancer 5) immune checkpoint inhibitors
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
Jason M. Redman, M.D.
Clinical Trials
Research
Combining immunotherapies and other anti-cancer treatments offers a means to engage (using tumor-targeted vaccines) the body’s immune system and then facilitate the immune system’s attack on the tumor (checkpoint inhibitors, cytokines, immunomodulators, chemotherapy, targeted therapy).
I am interested in applying these techniques to gastrointestinal cancer, head and neck cancer, and prostate cancer. I also conduct phase 1 clinical trials testing new drugs and combinations for any type of solid tumor.
By working closely with the scientists in the Laboratory of Tumor Immunology and Biology (LTIB), the Genitourinary Malignancies Branch (GMB) program aims to use correlative studies to help identify predictors of response to these treatments.
Publications
Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancer
Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer
Avelumab in Men With Metastatic Castration- Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine
Biography
Jason M. Redman, M.D.
Dr. Redman completed his B.S. degree in Philosophy and Biological Sciences at the University of Connecticut. He received his M.D. from New York Medical College. Between the third and fourth years of medical school, Dr. Redman was awarded a 1-year fellowship from the Doris Duke Charitable Research Foundation which he completed at the University of Iowa, Carver College of Medicine. After internal medicine training at Georgetown University Hospital, Dr. Redman completed a medical oncology fellowship at the National Cancer Institute (NCI). Prior to being named Assistant Research Physician, Dr. Redman was awarded the Society for Immunotherapy of Cancer Immunotherapy fellowship at the NCI.
Other awards include the Georgetown Internal Medicine Residency Eric Lemmer, M.D. Memorial Research Award (2016) for excellence in research and scholarly activity, and the New York Medical College Bessie Kaplan Morais Memorial Award (2013) for outstanding interest and ability in scientific investigation. Dr. Redman’s work was selected for podium presentation at the Doris Duke Clinical Research Fellowship Annual Meeting in 2012.
News
Ad-CEA vaccine plus avelumab vs mFOLFOX6-based standard care in untreated metastatic CRC
ESMO WCGIC 2020 (The Video Journal of Oncology)
In this interview, Dr. Redman discusses the randomized Phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer.
QuEST1 clinical trial updates
ESMO 2020 (The Video Journal of Oncology)
In this interview, Dr. Redman gives an overview of his presentation on QuEST1 clinical trial updates including the data and next steps for this therapy. This trial produced an exceptional response rate of 55.6% in unselected, castration-resistant prostate cancer patients.